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Abstract
Background: Human immunodeficiency virus (HIV) and hepatitis C virus (HCV) share common routes of  infection and 
as such, co-infection is expected. Co-infection of  the two viruses is of  great medical importance as it determines the effect 
of  drugs used for treatment at various stages.  
Objective: This interplay between HIV and HCV sets the tone for the objective of  this study which is to ascertain the sero-
prevalence of  HCV among newly diagnosed HIV patients in Ughelli, a suburban area of  Delta State, Nigeria.
Methods: A total of  200 newly diagnosed HIV-positive patients were recruited for this study. Each of  the sera was tested 
for anti-HCV antibody using SWE-life HCV ultra rapid test strip. Appropriate questionnaires were used to ascertain other 
important information which include social behaviour such as whether the patients were MSM (males), IDU, tattoo and/or 
have received blood transfusion in the past.
Results: The prevalence of  HCV among the study population was determined to be 15.0%. A higher seroprevalence was 
observed among females (16.5%) than in males (13.0%). A higher seroprevalence was also observed among age groups >26 
years (16.0%) than in age-groups 14-25 years (13.0%) and 2-13 years (0.0%). Of  the 7 patients with tattoos, 1(14.3%) tested 
positive for HCV compared to 29(15.0%) with no tattoos. We found no significant correlation with transfusion, intravenous 
drug use (IDU), men that have sex with men (MSM), tattooing and the seroprevalence of  HCV. However, significant corre-
lation existed with age, sex and HCV prevalence.
Conclusion: This study reports a 15.0% seroprevalence of  HCV among newly diagnosed HIV patients and that is alarm-
ingly well above several other studies done in the past in Nigeria and other countries of  sub-Saharan Africa. Planned preven-
tion, screening, and treatment are needed to reduce further transmission and morbidity. Future studies involving HCV-RNA 
assays are needed.
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Introduction
The human immunodeficiency virus (HIV) and hepati-
tis C virus (HCV) are known to share common routes 
of  transmission which include blood contact, mother-
to-child and sexual intercourse (both vertical and hori-
zontal transmission)1,2. There are relative variations in 
their infectivity with the different routes. HCV howev-
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er, has a higher tendency of  being contacted parenteral-
ly3,4. Due to the similarities in their routes of  transmis-
sion, epidemiologists have demonstrated the potential 
of  co-infection. Globally, the infection burden of  the 
hepatitis C alone is about 2.3% affecting up to 150-200 
million people while that of  HIV is about 0.8% with 
an estimated number of  32.2–38.8 million people living 
with HIV worldwide5-7.
Sub-Saharan Africa has the highest prevalence of  HIV 
infection (4.7%) with 25 million people living with the 
virus.  In Nigeria, the estimated number of  people leav-
ing with HIV is about 3 million7. In addition to this 
high prevalence, UNAIDS reports certain behavioural 
changes which could encourage increased HIV infec-
tion and also predispose infected individuals to HCV 
infection in sub-Saharan Africa. These changes include 
a decrease in the use of  condoms and/or increase in the 
number of  sexual partners. The report also revealed no 
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noticeable change in HIV burden among intravenous 
drug users (IDU)7. 
HCV occurrence among people living with HIV has 
long been reported. This is of  great medical impor-
tance as 80% HCV infection are usually found to be 
chronic, especially when the patient is infected through 
blood contact such as intravenous drug use (IDUs) and 
blood transfusion4,8,9. In general, the overall clinical out-
come of  HCV infection could be self-limiting in which 
case there is clearance of  infection, persistent showing 
or high clinical manifestation such as liver cirrhosis and 
subsequently liver failure or hepatocellular carcino-
ma3,10,11.
In recent times, several researches establish a relation-
ship between HIV and progression of  HCV infection 
and show that at each stage, co-infection with HIV in-
fluences the clinical outcome of  the HCV infection3,10,12. 
Mehta and colleagues13 reported the inability of  HCV 
patients with history of  IDUs who were co-infected 
with HIV to clear HCV from their system compared 
to when they were infected with HIV alone. Reports 
show that 20.0% of  HCV acutely infected individuals 
clear the virus. This number is reduced to 5.0%-10.0% 
when infected with HIV and is even lower with lower 
CD4+ lymphocyte counts9,12,14. Rapid progression of  
persistent HCV to cirrhosis and/or hepatocellular car-
cinoma has also been shown to be associated with HIV 
co-infection15-18.
Apart from the influence of  HIV on the progression 
of  HCV infection, reports also suggest that there are 
higher chances of  the HCV-HIV co-infected patients 
to develop HAART-associated hepatotoxicity due to 
treatment of  the HIV with antiretroviral drugs3,19. This 
situation is worth paying adequate attention to during 
drug administration. On the other hand, studies are still 
ongoing to establish influence of  HCV on the progres-
sion of  HIV3,20-22.
This interplay between HIV and HCV sets the tone 
for the objective of  this study which is to ascertain the 
seroprevalence of  HCV among newly diagnosed HIV 
patients in Ughelli, a suburban area of  Delta State, Ni-
geria. This would help in the clinical management of  
the HIV-HCV co-infected patients especially  in the 
choice and administration of  highly active antiretroviral 
therapy (HAART) and will reduce the high incidence 
of  drug-induced hepatoxicity commonly found among 




Ughelli North local government area of  Delta State, 
Nigeria has a population of  about 321,028 people with 
a land mass of  1440 square Kilometre (NPC, 2006). It 
is a semi-urban area with predominantly Urhobo eth-
nic group but due to oil exploration in the area there 
is heavy influx of  several other ethnic groups from all 
over Nigeria. The General hospital, Ughelli lies along 
the border belt that connects Delta State and Rivers 
State. The hospital serves both children and adult pa-
tients in a primarily semi-urban area of  Delta State, Ni-
geria. Therefore, the hospital provides a wide coverage 
of  the population in this region.
Study population
The samples for this study were collected from newly 
diagnosed HIV patients attending the General hospital 
Ughelli, Delta State, Nigeria after due permission was 
obtained from the hospital management/ethical com-
mittee. Blood samples were collected from two hun-
dred consented HIV patients.
Patient eligibility and inclusion criteria
Out-patients ≥2 years of  age present at the participating 
hospital who voluntarily provided informed consent/
assent to participate in the study were eligible. As the in 
the case of  minors who their parents/guardian volun-
tarily provided informed consent/assent to participate 
in the study were eligible. All those unwilling to provide 
informed consent/assent for participating in the study 
and those aged below 2 years were not eligible.
 
Sample collection and processing
Samples were collected from two hundred (200) partic-
ipants (including men, women and children) who were 
newly diagnosed of  HIV. Appropriate questionnaires 
were used to ascertain other important information 
which include social behaviours such as whether the 
patients were MSM (as in the case of  males), IDU, tat-
too and/or have received blood transfusion in the past. 
Samples were collected between June 2012 and Febru-
ary 2013 from consented/assented participants after 
due permission was obtained from the hospital man-
agement/ethical committee. Five millilitres of  venous 
blood was collected aseptically from the participants 
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into sterile ethylene-diamine-tetra-acetate (EDTA) bot-
tles and centrifuged at 1300 x g for 10min. Plasma from 
the samples were stored in two aliquots at -200C before 
carrying out other laboratory procedures.
Serological analysis
Plasma was tested for the presence of  anti-HCV anti-
body using in vitro diagnostic kit, SWE-life HCV ultra 
rapid test strip, a qualitative, solid phase two site sand-
wich immunoassay. Samples were analysed and results 
interpreted according to the manufacturer’s specifica-
tions. Each sample was tested in duplicate to ensure re-
producibility.
Data analysis
All data was collected both from the questionnaire and 
the test results. The former was used for demographical 
analysis while the latter data was analysed to determine 
a relationship of  co-infection between HIV and HCV 
among newly diagnosed HIV patient using statistical 
difference assessed by student t-test. Prism 6 software 
was used for these analyses.
Results
A total of  two hundred patients’ blood samples of  
newly diagnosed of  HIV were analysed for anti-HCV 
antibody. One hundred and fifteen (57.5%) were fe-
males out of  the total number while eighty five (42.5%) 
were males (Table 1). Based on age the highest num-
ber of  the patient was the age bracket 26 years and 
above (73.0%, n=146) followed by age bracket 14-25 
years (25.0%, n=50) and age bracket 2-13 years were 
the least (2.0%, n=4) Table 1. One hundred and ninety 
six (98.0%) of  our participants had no history of  blood 
transfusion. Based on social behavior, none (0.0%) of  
our participant admitted to be involved in intravenous 
drugs or men that sleep with men (0.0%). Seven (3.5%) 
had traditional tattoos while 193(96.5%) had no tattoo 
(Table 1).
Table 1: Baseline characteristics of the participants 
Variables  No. Tested (%)   
Sex    
Males  85(42.5) 
Females  115(57.5) 
Age groups (years)   
2-13 4(2.0) 
14-25 50(25.0) 
26 & above 146(73.0) 
Predisposition factors    
Intravenous drug users (IDUs)   
Yes  0(0.0) 
No 200(100.0) 
Blood/blood product transfusion   
Yes  4(2.0) 
No 196(98.0) 
men that have sex with men (MSM)   
Yes  0(0.0) 
No 200(100.0) 
Tattoo   
Yes  7(3.5) 
No 193(96.5) 
Total  200(100.0) 
 
Of  the 200 patients tested, 30(15.0%) were positive for HCV while 170 (85.0%) were negative (Figure 1). 
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The sex-related prevalence showed that females had 
higher prevalence compared to the male (13.0%) with 
the females as high as 16.5% (Figure 2). This sex-related 
difference was statistically significant (p<0.05).
Figure 2: HCV prevalence among people living with HIV by gender 
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Age-related prevalence showed a higher prevalence 
among age bracket 26 years and above (16.0%) com-
pared to their counterparts in age bracket 14-25 years 
with a prevalence of  13.0%. However, zero prevalence 
was found among age bracket 2-13 years of  age (Figure 
3). This age difference was also statistically significant 
(p<0.05).
Figure 3: HCV prevalence among people living HIV according age groups  





 Table 2 shows the predisposition factors and sero-
positive outcomes of  newly diagnosed HIV patients 
tested for HCV antibody. Of  the 7 patients with tat-
toos, 1(14.3%) tested positive for HCV compared to 
29(15.0%) with no tattoo. Other predisposing factors 
such as IDU, MSM and blood transfusion were not sig-
nificantly significant in this study (Table 2).
Table 2: Predisposition factors and seropositive outcomes of newly diagnosed HIV patients 
tested for HCV antibody 
Predisposition factors No. Tested (%)   No. Positive (%) P value 
Intravenous drug users (IDUs)       
Yes  0(0.0) 0(0.0)   
No 200(100.0) 30(15.0) P>0.05 
Blood/blood product transfusion       
Yes  4(2.0) 0(0.0)   
No 196(98.0) 30(15.3) P>0.05 
men that have sex with men (MSM)       
Yes  0(0.0) 0(0.0)   
No 200(100.0) 30(15.0) P>0.05 
Tattoo       
Yes  7(3.5) 1(14.3)   
No 193(96.5) 29(15.0) P>0.05 
Total  200(100.0) 30(15.0)   
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Discussion
The objective of  this study was to ascertain the sero-
prevalence of  HCV among newly diagnosed HIV pa-
tients in Ughelli, a suburban area of  Delta State, Ni-
geria. Of  the 200 participants tested, 30(15.0%) were 
positive for HCV. The study showed statistically sig-
nificant (p<0.05) sex and age-related differences. Since 
the introduction of  highly active antiretroviral therapy 
(HAART) into the treatment of  HIV, the world has ex-
perienced high reduction in HIV-related deaths. Not-
withstanding, studies have shown that co-infection with 
other viruses has in fact dented this achievement re-
corded by the introduction of  HAART. One of  such 
virus is HCV, one of  the most common causes of  
chronic viral hepatitis, which has remained the com-
monest cause of  serious liver diseases among HIV-in-
fected individuals27-30. As highlighted earlier, human 
immunodeficiency virus (HIV) and hepatitis C virus(H-
CV) have common routes of  infection making it possi-
ble for both viruses to co-infect the same individual1,2,31. 
Of  the 32.2–38.8 million people living with HIV, about 
7 million individual (approximately 20.0-25.0%) are re-
ported to be co-infected with HCV. Prevalence varies 
with geographical region32,33.
In sub-Saharan Africa, it is estimated that the preva-
lence of  HCV among HIV-infected individuals is about 
3.0-7.0%5,34,35. This figure is much lower than the figure 
obtained in our study (15.0%) (Figure 1). Our figure 
is also higher than what was obtained in similar stud-
ies in Kenya, East Africa (10.0%), Senegal, West Africa 
(1.6%) and South Africa (13.4%)36-38 but lower than that 
of  another Eastern Africa state, Tanzania (18.1%)39. 
The difference in prevalence could be due to differenc-
es in social behaviour of  the individuals involved in this 
study and population size of  the individual countries40. 
Our result is consistent with previous results obtained 
elsewhere in South Western Nigeria by Balogun and 
colleagues (14.7%)41.
Among our participants, the HCV prevalence among 
the females (17.0%) is higher than in males (13.0%) 
(Figure 2), p= 0.8479. This is not statistically significant. 
This is in agreement with other past studies carried out 
in Nigeria41,42. This could be due to the fact that barring 
other routes of  contracting HIV and HCV, women are 
more likely to contract both viruses through unprotect-
ed sexual intercourse43.
The age 26 years and above in our study (Figure 3) was 
found to have the highest prevalence (16.0%) while 14-
25 years and 0-13 years are 13.0% and 0.0% respec-
tively. The result is at par with other figures from parts 
of  the world, which shows that there is higher chances 
of  co-infection of  HIV and HCV in an individual in-
creases with age39,44. As expected, there is higher sexual 
involvement at this age and higher tendency to contact 
the disease parenterally31.
As earlier stated, blood transfusion, IDU, men that have 
sex with men (MSM) and tattooing are important fac-
tors in HIV and HCV transmission but there was no 
statistical correlation between HIV and HCV infection 
and blood transfusion, IDU and tattooing in our study. 
Of  the 200 participants, 4 received blood/blood prod-
uct in the past, none was admitted to being an IDU or 
MSM and 7 had tattoos, but only one tested positive 
to anti-HCV. This might be because most of  the in-
fections are mostly through heterosexual activity other 
than those routes in this part of  the world45. Though, 
Ogunro et al.46 reported association of  scarification 
marks on women with infections like hepatitis C viral 
infection, presence of  tattoos did not significantly in-
fluence HCV prevalence among these study population. 
A study with a larger sample size in the same hospital 
might reveal otherwise. Alter et al.47 reported a strong 
association of  the receipt of  a blood transfusion before 
1990 with HCV infection. In the same vein, Reddy et 
al.48 observed that the risk of  dual HBV-HCV infection 
was greater among chronic renal failure patients, due to 
the frequent exposure to blood from transfusions and 
extracorporeal circulation during hemodialysis. Howev-
er, Bini and Perumalswami49 also observed no associa-
tion between blood transfusion prior to 1992 and HCV 
infection in the U.S. However in line with the assertion 
of  Oje et al.50, screening of  blood and blood products 
from donors is routinely done in all blood banks and 
in most health care facilities in Nigeria before transfu-
sion. This present study also reinforces the routine and 
compulsory screening of  all blood and blood products 
before transfusion or organ transplantation.
Limitations 
This study was not able to perform viral loads and did 
not attempt to assay for the presence of  HCV-RNA. 
However, the need for experienced staff, special lab-
oratory conditions and equipment and the need for 
standardization are drawbacks of  HCV RNA assays 
in comparison with HCV core Ag and anti-HCV anti-
body tests used in this study51,52. Future studies involv-
ing HCV-RNA assays are needed. Nevertheless, the 
findings of  this present study can serve to direct any 
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national effort aimed toward minimizing the spread of  
these viruses in Delta State, Nigeria. Nonetheless, our 
results are consistent with other studies50,53,54, and are 
relevant for improving the care of  HIV/AIDS patients 
in Nigeria.
Conclusion
The 15% seroprevalence of  HCV reported among 
newly diagnosed HIV patients in this study is alarm-
ingly well above several other studies done in the past 
in Nigeria and other countries of  sub-Saharan Africa. 
Planned prevention, screening, and treatment are need-
ed to reduce further transmission and morbidity. We 
recommend parallel enlightenment programme with 
HIV, to educate the populace on the dangers of  both 
infections and proper behaviour on the part of  those 
who already have either of  the two infections. We also 
recommend further studies at molecular level on the in-
fluence of  HCV on HIV progression.
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